Bimonthly leucovorin, infusion 5-fluorouracil, hydroxyurea, and irinotecan (FOLFIRI-2) for pretreated metastatic colorectal CancerMABRO, May; LOUVET, Christophe; ANDRE, Thierry et al.American journal of clinical oncology. 2003, Vol 26, Num 3, pp 254-258, issn 0277-3732, 5 p.Article

Chemotherapy for elderly patients with advanced colorectal carcinomaGALLEGO, Rosa; SANCHEZ, Nuria; MAUREL, Joan et al.Expert review of anticancer therapy. 2006, Vol 6, Num 5, pp 795-800, issn 1473-7140, 6 p.Article

Salvage treatment with single-agent capecitabine in patients with heavily pretreated advanced colorectal cancerARDAVANIS, Alexandros S; IOANNIDIS, Georgios N; ORPHANOS, George S et al.Anticancer research. 2006, Vol 26, Num 2B, pp 1669-1672, issn 0250-7005, 4 p.Article

Metastatic colorectal cancer: Current treatment and future options for improved survival: Medical approach - present statusGLIMELIUS, Bengt; CAVALLI-BJÖRKMAN, Nina.Scandinavian journal of gastroenterology. 2012, Vol 47, Num 3, pp 296-314, issn 0036-5521, 19 p.Article

Prognostic significance of Subjective Global Assessment (SGA) in advanced colorectal cancerGUPTA, D; LAMMERSFELD, C. A; VASHI, P. G et al.European journal of clinical nutrition. 2005, Vol 59, Num 1, pp 35-40, issn 0954-3007, 6 p.Article

Orthovoltage Intraoperative Radiotherapy for Locally Advanced and Recurrent Colorectal CancerDALY, Megan E; KAPP, Daniel S; MAXIM, Peter G et al.Diseases of the colon & rectum. 2012, Vol 55, Num 6, pp 695-702, issn 0012-3706, 8 p.Article

Multiorgan resections for advanced colorectal cancerVISOKAI, Vladimir; LIPSKA, Ludmila; BERGMANN, Pavel et al.Anticancer research. 2006, Vol 26, Num 4B, pp 3183-3186, issn 0250-7005, 4 p.Article

Bioelectrical impedance phase angle in clinical practice: implications for prognosis in advanced colorectal cancerGUPTA, Digant; LAMMERSFELD, Carolyn A; BURROWS, Jessica L et al.The American journal of clinical nutrition. 2004, Vol 80, Num 6, pp 1634-1638, issn 0002-9165, 5 p.Article

A Phase 2 trial of the liposomal DACH platinum L-NDDP in patients with therapy-refractory advanced colorectal cancerDRAGOVICH, Tomislav; MENDELSON, David; KURTIN, Sandra et al.Cancer chemotherapy and pharmacology. 2006, Vol 58, Num 6, pp 759-764, issn 0344-5704, 6 p.Article

Calpain 2-dependent IκBα degradation mediates CPT-11 secondary resistance in colorectal cancer xenograftsFENOUILLE, Nina; GROSSO, Sebastien; SU YUNCHAO et al.Journal of pathology (Print). 2012, Vol 227, Num 1, pp 118-129, issn 0022-3417, 12 p.Article

First clinical experience of orally active epidermal growth factor receptor inhibitor combined with simplified FOLFOX6 as first-line treatment for metastatic colorectal CancerZAMPINO, Maria Giulia; MAGNI, Elena; MASSACESI, Cristian et al.Cancer. 2007, Vol 110, Num 4, pp 752-758, issn 0008-543X, 7 p.Article

Predictive value of thymidylate synthase expression in advanced colorectal cancer patients receiving fluoropyrimidine-based chemotherapy : Evidence from 24 studiesQIU, Li-Xin; TANG, Qi-Yun; BAI, Jian-Ling et al.International journal of cancer. 2008, Vol 123, Num 10, pp 2384-2389, issn 0020-7136, 6 p.Article

Deficient mismatch repair system in patients with sporadic advanced colorectal cancerKOOPMAN, M; KORTMAN, Gam; MEKENKAMP, L et al.British journal of cancer. 2009, Vol 100, Num 2, pp 266-273, issn 0007-0920, 8 p.Article

A phase II study of fixed-dose capecitabine and assessment of predictors of toxicity in patients with advanced/metastatic colorectal cancerSHARMA, R; RIVORY, L; BEALE, P et al.British journal of cancer. 2006, Vol 94, Num 7, pp 964-968, issn 0007-0920, 5 p.Article

Cost-Minimization Analysis of Sequence Changes Between FOLFIRI and FOLFOX6 Therapy for Advanced Colorectal Cancer in JapanMIYAZAKI, Yoshiko; HARADA, Tomohiko; AKASE, Tomohide et al.Clinical therapeutics. 2009, Vol 31, Num THEM, pp 2433-2441, issn 0149-2918, 9 p., 2Article

Correlation of progression-free and post-progression survival with overall survival in advanced colorectal cancerPETRELLI, F; BARNI, S.Annals of oncology. 2013, Vol 24, Num 1, pp 186-192, issn 0923-7534, 7 p.Article

Reporting Time-to-Event Endpoints and Response Rates in 4 Decades of Randomized Controlled Trials in Advanced Colorectal CancerARKENAU, Hendrik-Tobias; NORDMAN, Ina; DOBBINS, Timothy et al.Cancer. 2011, Vol 117, Num 4, pp 832-840, issn 0008-543X, 9 p.Article

A prospective randomized study of irinotecan (CPT-11), leucovorin (LV) and 5-fluorouracil (5FU) versus leucovorin and 5-fluorouracil in patients with advanced colorectal carcinomaGENNATAS, C; PAPAXOINIS, G; MICHALAKI, V et al.Journal of chemotherapy. 2006, Vol 18, Num 5, pp 538-544, issn 1120-009X, 7 p.Article

Systemic treatment of advanced colorectal carcinoma : The systemic treatment of gastro-intestinal cancersVAN LAARHOVEN, Hanneke W. M; PUNT, Cornelis J. A.European journal of gastroenterology & hepatology. 2004, Vol 16, Num 3, pp 283-289, issn 0954-691X, 7 p.Article

Comorbidity, age and overall survival in cetuximab-treated patients with advanced colorectal cancer (ACRC)—results from NCIC CTG CO.17: a phase III trial of cetuximab versus best supportive careASMIS, T. R; POWELL, E; WHITTOM, R et al.Annals of oncology. 2011, Vol 22, Num 1, pp 118-126, issn 0923-7534, 9 p.Article

Triplet schedule of weekly 5-Fluorouracil and alternating irinotecan or oxaliplatin in advanced colorectal cancer: A dose-finding and phase II studyMORELLI, M. F; SANTOMAGGIO, A; GUGLIELMI, F et al.Oncology reports. 2010, Vol 23, Num 6, pp 1635-1640, issn 1021-335X, 6 p.Article

Biweekly cetuximab and irinotecan as third-line therapy in patients with advanced colorectal cancer after failure to irinotecan, oxaliplatin and 5-fluorouracilPFEIFFER, P; NIELSEN, D; BJERREGAARD, J et al.Annals of oncology. 2008, Vol 19, Num 6, pp 1141-1145, issn 0923-7534, 5 p.Article

Concurrent irinotecan, oxaliplatin and UFT in first-line treatment of metastatic colorectal cancer : a Phase I studySHEIKH, H. Y; VALLE, J. W; PALMER, K et al.British journal of cancer. 2007, Vol 96, Num 1, pp 38-43, issn 0007-0920, 6 p.Article

A randomized phase II trial evaluating safety and efficacy of an experimental chemotherapy regimen (irinotecan + oxaliplatin, IRINOX) and two standard arms (LV5-FU2 + irinotecan or LV5-FU2 + oxaliplatin) in first-line metastatic colorectal cancer : a study of the Digestive Group of the Fédération Nationale des Centres de Lutte Contre le CancerBECOUARN, Y; SENESSE, P; THEZENAS, S et al.Annals of oncology. 2007, Vol 18, Num 12, pp 2000-2005, issn 0923-7534, 6 p.Article

Increased tolerability of bimonthly 12-hour timed flat infusion 5-fluorouracil/irinotecan regimen in advanced colorectal cancer : A dose-finding studyFICORELLA, C; RICEVUTO, E; TINARI, N et al.Oncology reports. 2006, Vol 15, Num 5, pp 1345-1350, issn 1021-335X, 6 p.Article